|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B
Xupeng Hong1,*, Elena S. Kim2 andHaitao Guo2,*
Version of Record online: 6 NOV 2017
DOI: 10.1002/hep.29479
© 2017 by the American Association for the Study of Liver Diseases.
Hepatology
Volume 66, Issue 6, pages 2066–2077, December 2017
1 Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC
2 Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN
Email: Xupeng Hong ([email protected]), Haitao Guo ([email protected])
*ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Haitao Guo, Ph.D.
Department of Microbiology and Immunology, Indiana University School of Medicine
635 Barnhill Drive
Indianapolis, IN 46202
E-mail: [email protected]
Tel.: +1-317-274-0530; or
Xupeng Hong, M.S.
Department of Microbiology and Immunology, Georgetown University Medical Center
3900 Reservoir Road, Northwest
Washington, DC 20057
E-mail: [email protected]
Tel: +1-202-826-8139
Potential conflict of interest: Dr. Guo received grants from and owns stock in Arbutus. He received grants from Alios. He consults for Assembly.
Supported by NIH grants R01AI094474, R01AI110762, and R01AI123271.
Current Address for Xupeng Hong: Department of Microbiology and Immunology, Penn State University College of Medicine, Hershey, PA.
Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated. One major reason for failure of HBV treatment is the inability to eradicate or inactivate the viral covalently closed circular DNA (cccDNA), which is a stable episomal form of the viral genome decorated with host histones and nonhistone proteins. Accumulating evidence suggests that epigenetic modifications of cccDNA contribute to viral replication and the outcome of chronic HBV infection. Here, we summarize current progress on HBV epigenetics research and the therapeutic implications for chronic HBV infection by learning from the epigenetic therapies for cancer and other viral diseases, which may open a new venue to cure chronic hepatitis B. (Hepatology 2017;66:2066–2077)
|
|
发表于 2017-11-23 15:12